Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−141.35 USD
−18.95 M USD
226.00 K USD
2.28 M
About Traws Pharma, Inc.
Sector
Industry
CEO
Werner Cautreels
Website
Headquarters
Newtown
Founded
1998
FIGI
BBG000R338X6
Traws Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of TRAW is 11.61 USD — it has increased by 150.40% in the past 24 hours. Watch Traws Pharma, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Traws Pharma, Inc. stocks are traded under the ticker TRAW.
TRAW stock has risen by 160.25% compared to the previous week, the month change is a 173.26% rise, over the last year Traws Pharma, Inc. has showed a −36.98% decrease.
We've gathered analysts' opinions on Traws Pharma, Inc. future price: according to them, TRAW price has a max estimate of 6.00 USD and a min estimate of 6.00 USD. Watch TRAW chart and read a more detailed Traws Pharma, Inc. stock forecast: see what analysts think of Traws Pharma, Inc. and suggest that you do with its stocks.
TRAW reached its all-time high on Oct 4, 2013 with the price of 3,939,890,625.00 USD, and its all-time low was 4.06 USD and was reached on Nov 26, 2024. View more price dynamics on TRAW chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
TRAW stock is 29.45% volatile and has beta coefficient of 0.62. Track Traws Pharma, Inc. stock price on the chart and check out the list of the most volatile stocks — is Traws Pharma, Inc. there?
Today Traws Pharma, Inc. has the market capitalization of 38.03 M, it has increased by 1.22% over the last week.
Yes, you can track Traws Pharma, Inc. financials in yearly and quarterly reports right on TradingView.
Traws Pharma, Inc. is going to release the next earnings report on Apr 1, 2025. Keep track of upcoming events with our Earnings Calendar.
TRAW earnings for the last quarter are −8.81 USD per share, whereas the estimation was −6.25 USD resulting in a −40.96% surprise. The estimated earnings for the next quarter are −9.55 USD per share. See more details about Traws Pharma, Inc. earnings.
Traws Pharma, Inc. revenue for the last quarter amounts to 57.00 K USD, despite the estimated figure of 60.00 K USD. In the next quarter, revenue is expected to reach 60.00 K USD.
TRAW net income for the last quarter is −8.47 M USD, while the quarter before that showed −123.14 M USD of net income which accounts for 93.12% change. Track more Traws Pharma, Inc. financial stats to get the full picture.
No, TRAW doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 17.00 employees. See our rating of the largest employees — is Traws Pharma, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Traws Pharma, Inc. EBITDA is −24.08 M USD, and current EBITDA margin is −8.97 K%. See more stats in Traws Pharma, Inc. financial statements.
Like other stocks, TRAW shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Traws Pharma, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Traws Pharma, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Traws Pharma, Inc. stock shows the sell signal. See more of Traws Pharma, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.